P21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse

Abstract

Mice comprising a modified p21-activated kinase (Pak) inhibitor domain (PID*), optionally linked with GST and capable of constitutive expression of PID are provided. Also provided are cells, tissue, and organs obtainable from such mice, and methods for producing mice comprising a modified p21-activated kinase (Pak) inhibitor domain (PID*).

1 - 10 . (canceled) 
     
     
         11 . A transgenic mouse, comprising a genomically integrated transgene, wherein the transgene >is integrated into a safe harbor locus, wherein the transgene comprises>a stop cassette flanked by lox P sites upstream of a modified p21-activated (Pak) inhibitor domain (PID*) sequence (SEQ ID NO:1), wherein the stop cassette prevents expression of SEQ ID NO:1, and wherein upon exposure to CRE recombinase the stop cassette is excised from the mouse genome such that SEQ ID NO:1 is expressed. 
     
     
         12 . The transgenic of  claim 11 , wherein the transgene comprises SEQ ID NO:2. 
     
     
         13 . The transgenic mouse of  claim 11 , wherein the transgene comprises SEQ ID NO:3. 
     
     
         14 . A transgenic mouse, comprising a genomically integrated transgene, wherein the transgene is integrated into a safe harbor locus, wherein the transgene comprises a modified p21-activated (Pak) inhibitor domain (PID*) sequence (SEQ ID NO:1), wherein the integration comprises a gateway enzyme mix/catalyzed recombination. 
     
     
         15 . The transgenic mouse of  claim 14 , wherein the transgene comprises a stop cassette flanked by lox P sites upstream of the modified p21-activated (Pak) inhibitor domain (PID*) sequence (SEQ ID NO:1). 
     
     
         16 . The transgenic mouse of  claim 15 , wherein the stop cassette prevents expression of SEQ ID NO:1. 
     
     
         17 . The transgenic mouse of  claim 14 , wherein the gateway enzyme mix/catalyzed recombination comprises a CRE recombinase. 
     
     
         18 . The transgenic mouse of  claim 17 , wherein the transgene comprises a stop cassette flanked by lox P sites upstream of the modified p21-activated (Pak) inhibitor domain (PID*) sequence (SEQ ID NO:1), and wherein upon exposure to CRE recombinase the stop cassette is excised from the mouse genome such that SEQ ID NO:1 is expressed. 
     
     
         19 . The transgenic mouse of  claim 14 , wherein the transgene comprises SEQ NO:2. 
     
     
         20 . The transgenic mouse of  claim 14 , wherein the t transgene comprises SEQ ID NO:3. 
     
     
         21 . A transgenic mouse, comprising an integrated transgene, wherein the transgene comprises a nucleic acid sequence encoding a modified p21-activated kinase (Pak) inhibitor domain (PID*) linked to Glutathione S-transferase (GST), wherein the modified p21-activated kinase (Pak) inhibitor domain (PID*) linked to Glutathione S-transferase (GST) is constitutively expressed. 
     
     
         22 . The transgenic mouse of  claim 21 , wherein the transgene comprises SEQ ID NO:2. 
     
     
         23 . The transgenic mouse of  claim 21 , wherein the transgene comprises SEQ ID NO:3. 
     
     
         24 . The transgenic mouse of  claim 21 , wherein the transgene is integrated into a safe harbor locus. 
     
     
         25 . The transgenic mouse of  claim 21 , wherein the transgene is constitutively expressed in the list consisting of a cell, a tissue, and an organ. 
     
     
         26 . The transgenic mouse of  claim 25 , wherein the cell, the tissue, and the organ are selected from the group consisting of skin, tongue, esophagus, stomach, intestine, colon, mesothelium, Schwann cells, thyroid, and ovaries.